Naperville, IL, United States of America

James G Timmins

This inventor holds 10 USPTO granted patents. Top assignees: Pharmacia & Upjohn Company, The Upjohn Co.. Active years: 1991-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James G Timmins. Retrieved from https://idiyas.com/inventor/james-g-timmins

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 90.0

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Cambridge, MA (US) (1991)
Madison, WI (US) (2001)
Naperville, IL (US) (1991 - 2005)

Company Filing History:

7 out of 523

Pharmacia & Upjohn Company

Years Active: 1991-2005

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6858385 - Pseudorabies virus protein (2005-02-22),

2. 6521231 - Pseudorabies virus protein (2003-02-18),

3. 6261563 - Pseudorabies virus protein (2001-07-17),

4. 6255078 - Pseudorabies virus protein cross reference to related applications (2001-07-03),

5. 6251634 - Pseudorabies virus protein (2001-06-26),

6. 6172186 - Pseudorabies virus protein (2001-01-09),

7. 5674709 - Pseudorabies virus protein (1997-10-07),

8. 5352575 - Pseudorabies virus protein (1994-10-04),

9. 5041536 - Pseudorabies virus (PRV) gene (1991-08-20),

10. 5041370 - Pseudorabies virus (PRV) gene, host cell, method for detecting animals (1991-08-20),

Title: **James G Timmins: Innovator in Veterinary Science**

Introduction

James G Timmins, a notable inventor based in Naperville, IL, has made significant contributions to the field of veterinary science through his innovative research and patented inventions. With a total of ten patents to his name, Timmins has focused his work primarily on the development of vaccines and recombinant DNA technologies, particularly aimed at combating viral diseases in animals.

Latest Patents

Among his latest patents is a revolutionary invention pertaining to the pseudorabies virus (PRV). This invention provides recombinant DNA molecules that comprise sequences encoding PRV glycoproteins, specifically gI, gp50, and gp63. These innovations also detail transformative methods for host cells utilizing these recombinant DNA sequences and the corresponding polypeptides. Furthermore, the invention includes the development of subunit vaccines for PRV, methodologies for safeguarding animals against PRV infection, and techniques for differentiating between infected and vaccinated animals, showcasing Timmins's commitment to advancing veterinary health.

Career Highlights

Throughout his career, James G Timmins has collaborated with esteemed companies such as Pharmacia & Upjohn Company and The Upjohn Company, where he applied his expertise in biotechnology and animal health. His work has been pivotal in the progression of pharmaceutical advancements in treating and preventing animal diseases.

Collaborations

Timmins has also collaborated with other notable professionals in his field, including Leonard Edwin Post and Erik Aivars Petrovskis. These collaborations have further enriched his research and have been instrumental in bringing innovative solutions to market, benefiting both veterinary practices and animal welfare.

Conclusion

James G Timmins stands out as a significant figure in the realm of veterinary innovation. His contributions, particularly in the area of pseudorabies virus research and vaccine development, reflect his dedication to improving animal health. As he continues to pursue advancements in biotechnology, his work will undoubtedly inspire future inventors in the industry.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]